Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Charles Kunos"'
Autor:
Jason W. Sohn, Haksoo Kim, Samuel B. Park, Soyoung Lee, James I. Monroe, Thomas B. Malone, Timothy Kinsella, Min Yao, Charles Kunos, Simon S. Lo, Robert Shenk, Mitchell Machtay
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
PurposeTo reduce patient and procedure identification errors by human interactions in radiotherapy delivery and surgery, a Biometric Automated Patient and Procedure Identification System (BAPPIS) was developed. BAPPIS is a patient identification and
Externí odkaz:
https://doaj.org/article/91de23ed331a437fb5691c930617c0db
Autor:
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Galloway, Erica Golemis, Alice Li, Jeffrey Shoop, Stuart Wong, Ranee Mehra, Heath Skinner, Nabil F Saba, Elsa R Flores, Jeffrey N Myers, James M Ford, Rachel Karchin, Robert L Ferris, Charles Kunos, Jean M Lynn, Shakun Malik
Publikováno v:
JNCI: Journal of the National Cancer Institute. 114:1619-1627
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus–negative disease. As mutations in the TP53 gene are associated with worse outcomes in HN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac60138b8df09dbba2ae3932d5b6953
https://doi.org/10.1093/jnci/djac163
https://doi.org/10.1093/jnci/djac163
Autor:
Jerry M. Collins, Charles Kunos, Kimberly D. Hill, Lawrence W. Anderson, John Vatkevich, Kayla Rosati, Andrew Schumacher, Thomas DiPetrillo, Susan Wiersma, Howard Safran, Timothy Kinsella
Supplementary Pharmacokinetic Methods and Analyses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dd8e45f8c60bdae970ed4bdbc6f3dee
https://doi.org/10.1158/1078-0432.22471832
https://doi.org/10.1158/1078-0432.22471832
Abstract CT221: Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC
Autor:
Aman Chauhan, Jill Kolesar, Donglin Yan, Zhonglin Hao, Ronald McGarry, John Villano, Ralph Zinner, Ashish Maskey, Jordan Miller, Timothy Mullett, Aman Khurana, Xitong Zhou, Garima Gupta, Daniel Flora, Colleen Darnell, Richard O'Neil, Charles Kunos, Mark B. Evers, Lowell Anthony, Susanne Arnold
Publikováno v:
Cancer Research. 83:CT221-CT221
Purpose: Immune checkpoint inhibitor (ICI) maintenance therapy is standard of care for frontline management of extensive stage small cell lung cancer (ES SCLC). However, overall survival benefit of addition of ICI maintenance to frontline ES SCLC tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35b8543b29f48a807c2575a354336de9
https://doi.org/10.1158/1538-7445.am2023-ct221
https://doi.org/10.1158/1538-7445.am2023-ct221
Autor:
Aman Chauhan, Susanne Arnold, Jill Kolesar, William Carson, Heidi Weiss, Rani Jayswal, Donglin Yan, Riham El Khouli, Aman Khurana, Jan Beumer, Heloisa Soares, Mary Mulcahy, Thorvardur Halfdanarson, Daneng Li, Heather Jacene, Percy Ivy, Elise Kohn, John Wright, Larry Rubinstein, Zeta Chow, Piotr Rychahou, Mark B. Evers, Charles Kunos, Lowell Anthony, Bhavana Konda
Publikováno v:
Cancer Research. 83:CT194-CT194
Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::153d93440cbd3c1178cb4a33de2f5aaf
https://doi.org/10.1158/1538-7445.am2023-ct194
https://doi.org/10.1158/1538-7445.am2023-ct194
Autor:
Jan H. Beumer, Sarah Behr, Holly Gallion, John Vargo, Frederick Ueland, Haider Mahdi, Brian Orr, Eugenia Girda, Susan Christner, Edward Chu, Charles Kunos, Percy S. Ivy, Sarah Taylor
Publikováno v:
Cancer Research. 83:2800-2800
Background: Locally advanced cervical cancer accounts for most deaths from disease. Standard of care includes treatment with cisplatin-based chemoradiation with a 70% response rate. The addition of intravenous (IV) triapine to chemoradiation has show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db5e2c5073a0d3f1f76030167064dc85
https://doi.org/10.1158/1538-7445.am2023-2800
https://doi.org/10.1158/1538-7445.am2023-2800
Autor:
Aman Chauhan, Susan M. Christner, Jan Hendrik Beumer, Charles Kunos, Aman Khurana, Riham El Khouli, Heidi Weiss, Donglin Yan, Heloisa P. Soares, Thorvardur Ragnar Halfdanarson, Daneng Li, William Edgar Carson, Mark B Evers, Percy Ivy, Elise C. Kohn, Larry Rubinstein, Susanne M. Arnold, Jill Kolesar, Lowell Brian Anthony, Bhavana Konda
Publikováno v:
Journal of Clinical Oncology. 41:648-648
648 Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate, and thus repair of DNA in this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::651c1a9f6ed7cd98f24e95014444c910
https://doi.org/10.1200/jco.2023.41.4_suppl.648
https://doi.org/10.1200/jco.2023.41.4_suppl.648
Autor:
Sani Kizilbash, David Piccioni, Solmaz Sahebjam, John Villano, Kurt Jaeckle, Mary Welch, Xiao-Tang Kong, Matthias Holdhoff, Anita Lammers, Adam Remick, Joel Reid, Jacob Allred, John Port, Ian Lanza, Samuel McBrayer, Charles Kunos, Geoffrey Shapiro, Alex Adjei
Publikováno v:
Neuro-Oncology. 24:vii75-vii75
IDH mutant gliomas depend on glutaminase for glutamate/glutathione generation from glutamine because R-2-hydroxyglutarate inhibits branched chain amino acid transaminase mediated glutamate biosynthesis. Telaglenastat (CB-839 HCl) is a potent glutamin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a65d7891ba114c11ca3c5eab64fb1b3
https://doi.org/10.1093/neuonc/noac209.288
https://doi.org/10.1093/neuonc/noac209.288
Autor:
Julie Hong, Martin Brechbiel, Jeff Buchsbaum, Christie A. Canaria, C. Norman Coleman, Freddy E. Escorcia, Michael Espey, Charles Kunos, Frank Lin, Deepa Narayanan, Jacek Capala
Publikováno v:
European journal of nuclear medicine and molecular imaging. 49(1)
Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality.This article reviews National Cancer Institute (NCI)'s support of RPT through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763f4b0922370eac97faa0c4c5ef6a96
https://pubmed.ncbi.nlm.nih.gov/34378064
https://pubmed.ncbi.nlm.nih.gov/34378064
Autor:
Zin Myint, William H. St Clair, Peng Wang, Riham Khouli, Bryan P Lemieux, Dennis Cheek, Donglin Yan, Charles Kunos
Publikováno v:
Journal of Clinical Oncology. 40:TPS5095-TPS5095
TPS5095 Background: Most patients with metastatic castration resistant prostate cancer (mCRPC) develop bone metastases with debilitating pain that is itself associated with shorter survival. Several bone-seeking radionuclides have been developed for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe7528a689a64dd70bb1fe8f2cf7c069
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5095
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5095